On the right is a selection of recent articles of medical News, E-medicine, Nursing, Pediatrics, Hospitals and Heath Care and Patient Safety.


Friday, September 07, 2007

Just in from PubMed ! Articles by CMH Physicians

Voronov P. Przybylo HJ. Jagannathan N.
Institution Department of Anesthesiology, Children's Memorial Hospital, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Title
Apnea in a child after oral codeine: a genetic variant - an ultra-rapid
metabolizer
.
Source
Paediatric Anaesthesia. 17(7):684-7, 2007 Jul.
Abstract
We present a case of a 29 months old previously healthy child who experienced apnea resulting in brain injury following a dose of acetaminophen and codeine 2 days after an uneventful anesthetic for tonsillectomy. A genetic polymorphism leading to ultra-rapid metabolism of
codeine into morphine resulted in narcosis and apnea. This paper discussesthe use of codeine for pain relief, obstructive sleep apnea, the alteration of the CYP2D6 gene and the resulting effect on drug metabolism.


Burke MJ. Walterhouse DO. Jacobsohn DA. Duerst RE. Kletzel M.
Institution
Division of Hematology, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60614-3394, USA.
Title
Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
[see comment].
Comment in: Pediatr Blood Cancer. 2007 Aug;49(2):115-6; PMID: 17474114
Source
Pediatric Blood & Cancer. 49(2):196-8, 2007 Aug.
Abstract
The role of tandem high-dose chemotherapy (HDC) with autologous peripheral hematopoietic progenitor cell rescue (APHPCR) in patients with Ewing Family Tumors (EFT) is controversial. We initiated treatment for eight consecutive patients with high-risk EFT with HDC and APHPCR from 1992 to 2003. There were no treatment related deaths. Four patients remain in
complete remission, including three who did not undergo local therapy to bone at either the primary or metastatic sites. Our experience has shown that treatment of EFT patients with tandem HDC with APHPCR may benefit a subgroup of high-risk patients in whom optimal local therapy is not
possible.